Literature DB >> 20225188

Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study.

Martin Heni1, Jürgen Machann, Harald Staiger, Nina F Schwenzer, Andreas Peter, Fritz Schick, Claus D Claussen, Norbert Stefan, Hans-Ulrich Häring, Andreas Fritsche.   

Abstract

BACKGROUND: The pathogenesis of type 2 diabetes is characterized by insulin resistance and beta-cell dysfunction. Pancreatic fat load may add to the development of beta-cell dysfunction. The aim was to thoroughly quantify the fat content of pancreas sections (caput, corpus, and cauda) and to compare the impact of pancreatic, intrahepatic, and visceral fat on insulin secretion in humans.
METHODS: Fifty-one subjects were subjected to an oral glucose tolerance test (OGTT) with glucose, insulin, and C-peptide measurements [28 subjects displayed normal glucose tolerance, 23 impaired fasting glycemia (IFG)] and/or impaired glucose tolerance (IGT)], and also to whole-body magnetic resonance imaging (MRI), pancreas MRI, and liver magnetic resonance spectroscopy (MRS).
RESULTS: After adjustment for gender and age, the mean pancreatic fat content was positively associated with body mass index (BMI), visceral adipose tissue (VAT), and waist circumference (all p < or = 0.0013). The mean pancreatic fat content was negatively associated with OGTT-based measures of insulin secretion (all p < or = 0.03). Analysis of the subgroups of glucose tolerance showed that this was restricted to subjects with IGT and/or IFG. Visceral fat also represented a determinant of beta-cell function in individuals with IGT and/or IFG (all p < or = 0.02), whereas intrahepatic fat did not. In a stepwise multivariate regression analysis, pancreatic fat turned out to be a stronger determinant of impaired insulin secretion than visceral fat.
CONCLUSIONS: Pancreatic fat is negatively associated with insulin secretion in subjects with IGT/IFG and, therefore, might represent an additional pathogenetic factor leading to beta-cell dysfunction. Copyright 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20225188     DOI: 10.1002/dmrr.1073

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  87 in total

1.  Pancreatic triacylglycerol distribution in type 2 diabetes. Reply to Hollingsworth K. G., Al Mrabeh A., Steven S. et al [letter].

Authors:  Paul Begovatz; Alessandra Bierwagen; Jesper Lundbom; Michael Roden
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

Review 2.  The clinical significance of pancreatic steatosis.

Authors:  Mark M Smits; Erwin J M van Geenen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02-08       Impact factor: 46.802

Review 3.  Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking.

Authors:  Bettina Mittendorfer
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-11       Impact factor: 4.294

4.  Pancreatic steatosis: Is it related to either obesity or diabetes mellitus?

Authors:  Raffaele Pezzilli; Lucia Calculli
Journal:  World J Diabetes       Date:  2014-08-15

5.  Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.

Authors:  Russell Rosenblatt; Amit Mehta; David Snell; Erika Hissong; Andrea Siobhan Kierans; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2018-09-29       Impact factor: 3.199

6.  Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans.

Authors:  Paul Begovatz; Chrysi Koliaki; Katharina Weber; Klaus Strassburger; Bettina Nowotny; Peter Nowotny; Karsten Müssig; Jürgen Bunke; Giovanni Pacini; Julia Szendrödi; Michael Roden
Journal:  Diabetologia       Date:  2015-03-05       Impact factor: 10.122

7.  Ectopic fat deposition in prediabetic overweight and obese minority adolescents.

Authors:  Claudia M Toledo-Corral; Tanya L Alderete; Houchun H Hu; Krishna Nayak; Sherryl Esplana; Ting Liu; Michael I Goran; Marc J Weigensberg
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

8.  Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Authors:  N S Patel; M R Peterson; D A Brenner; E Heba; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

9.  Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Michele Di Martino; Caterina Anania; Gian Marco Andreoli; Mario Bezzi; Carlo Catalano; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

10.  Prevention of Diabetes: Countless Opportunities and Clear Challenges.

Authors:  Anoop Misra
Journal:  Am J Lifestyle Med       Date:  2017-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.